{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Status+Epilepticus",
    "query": {
      "condition": "Refractory Status Epilepticus"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Status+Epilepticus&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:19:54.977Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03154307",
      "title": "Repeated TMS at Low Frequencies to Reduce Seizure Occurrence",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Epilepsy",
        "Status Epilepticus",
        "Epilepsia Partialis Continua",
        "Epilepsia Partialis Continua, Refractory (Medically)"
      ],
      "interventions": [
        {
          "name": "Low frequency repeated TMS (LF-rTMS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Baptist Health South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2,
      "start_date": "2016-02-19",
      "completion_date": "2019-08-23",
      "has_results": true,
      "last_update_posted_date": "2023-06-23",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03154307"
    },
    {
      "nct_id": "NCT02726867",
      "title": "Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy",
        "Status Epilepticus"
      ],
      "interventions": [
        {
          "name": "levetiracetam",
          "type": "DRUG"
        },
        {
          "name": "lacosamide",
          "type": "DRUG"
        },
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Phenobarbital",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mid-Atlantic Epilepsy and Sleep Center, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-02",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2017-08-29",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02726867"
    },
    {
      "nct_id": "NCT00265616",
      "title": "Treatment of Refractory Status Epilepticus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Status Epilepticus"
      ],
      "interventions": [
        {
          "name": "propofol",
          "type": "DRUG"
        },
        {
          "name": "thiopental/pentobarbital",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2006-05",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2013-04-09",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00265616"
    },
    {
      "nct_id": "NCT07177235",
      "title": "Ketamine for the Treatment of Refractory Status Epilepticus",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Refractory Status Epilepticus"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-11",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07177235"
    },
    {
      "nct_id": "NCT01796574",
      "title": "Ketogenic Diet for Refractory Status Epilepticus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Status Epilepticus",
        "Seizure",
        "Epilepsy",
        "Refractory Status Epilepticus",
        "Medically Resistant Status Epilepticus"
      ],
      "interventions": [
        {
          "name": "Ketogenic diet",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2012-11",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2017-03-14",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Honolulu, Hawaii • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01796574"
    },
    {
      "nct_id": "NCT04378075",
      "title": "A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Mitochondrial Diseases",
        "Drug Resistant Epilepsy",
        "Leigh Disease",
        "Leigh Syndrome",
        "Mitochondrial Encephalopathy (MELAS)",
        "Pontocerebellar Hypoplasia Type 6 (PCH6)",
        "Alpers Disease",
        "Alpers Syndrome"
      ],
      "interventions": [
        {
          "name": "Vatiquinone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "Up to 20 Years"
      },
      "enrollment_count": 68,
      "start_date": "2020-09-28",
      "completion_date": "2023-12-27",
      "has_results": true,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 12,
      "location_summary": "San Diego, California • Stanford, California • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04378075"
    },
    {
      "nct_id": "NCT02052739",
      "title": "Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Super-refractory Status Epilepticus"
      ],
      "interventions": [
        {
          "name": "SAGE-547",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2014-03-21",
      "completion_date": "2015-05-03",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Sarasota, Florida • Chicago, Illinois + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052739"
    },
    {
      "nct_id": "NCT07281027",
      "title": "COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "New Onset Refractory Status Epilepticus",
        "New-Onset Refractory Status Epilepticus",
        "Febrile Infection-Related Epilepsy Syndrome (FIRES)"
      ],
      "interventions": [
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Standard medical treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 438,
      "start_date": "2026-07-01",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07281027"
    },
    {
      "nct_id": "NCT02477618",
      "title": "A Study With SAGE-547 for Super-Refractory Status Epilepticus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Super-Refractory Status Epilepticus"
      ],
      "interventions": [
        {
          "name": "SAGE-547",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2015-06",
      "completion_date": "2017-08-11",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 100,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 76 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477618"
    },
    {
      "nct_id": "NCT05684978",
      "title": "Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Refractory Status Epilepticus"
      ],
      "interventions": [
        {
          "name": "Perampanel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wayne State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 1,
      "start_date": "2025-10-10",
      "completion_date": "2025-10-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-05-22T04:19:54.977Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05684978"
    }
  ]
}